Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer

Conclusions: Our findings suggest that treatment at HVF is associated with improved overall survival among stage III NSCLC patients receiving definitive CCRT, independent of academic affiliation. Further research is needed to determine whether or not efforts supporting centralization of radiotherapy at HVF will improve population-based survival, toxicities, and costs. Copyright (C) 2015 by the International Association for the Study of Lung Cancer
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Original Articles Source Type: research